新加坡生物科技独角兽Mirxes觅瑞正式纳入港股通,开启北水投资新渠道

21世纪经济报道
Sep 06, 2025

新加坡癌症早筛龙头企业Mirxes Holding Limited(股票代号:02629.HK,下称“Mirxes觅瑞”),自2025年5月23日在港交所主板上市后,仅用不足四个月便先后纳入恒生综合指数与港股通标的,其价值获国际市场高度认可,也为内地投资者开辟了参与生物科技独角兽成长的新路径。  2025年9月5日香港交易所收市后,恒生指数公司季度检讨结果正式生效,Mirxes觅瑞成功跻身沪港通下...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10